Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

AZD1480

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AstraZeneca

Drug class:

JAK2 inhibitor, JAK1 inhibitor

Related drugs:

RET-PTC1 rearrangement	Thyroid Gland Papillary Carcinoma	RET-PTC1 rearrangement	Thyroid Gland Papillary Carcinoma	AZD1480 Sensitive: D – Preclinical AZD1480 Sensitive : D	AZD1480 Sensitive: D – Preclinical AZD1480 Sensitive : D
RET C634W	Thyroid Gland Papillary Carcinoma	RET C634W	Thyroid Gland Papillary Carcinoma	AZD1480 Sensitive: D – Preclinical AZD1480 Sensitive : D	AZD1480 Sensitive: D – Preclinical AZD1480 Sensitive : D
RET M918T	Thyroid Gland Papillary Carcinoma	RET M918T	Thyroid Gland Papillary Carcinoma	AZD1480 Sensitive: D – Preclinical AZD1480 Sensitive : D	AZD1480 Sensitive: D – Preclinical AZD1480 Sensitive : D
RET rearrangement	Thyroid Gland Carcinoma	RET rearrangement	Thyroid Gland Carcinoma	AZD1480 Sensitive: D – Preclinical AZD1480 Sensitive : D	AZD1480 Sensitive: D – Preclinical AZD1480 Sensitive : D
PTCH1 rearrangement	Thyroid Gland Carcinoma	PTCH1 rearrangement	Thyroid Gland Carcinoma	AZD1480 Sensitive: D – Preclinical AZD1480 Sensitive : D	AZD1480 Sensitive: D – Preclinical AZD1480 Sensitive : D